Track topics on Twitter Track topics that are important to you
Atrial fibrillation (AF) impacts the lives of 30 million people worldwide. Pulmonary vein isolation (PVI) by catheter ablation is effective for paroxysmal AF, but the success rate remains marginal at 60-80%. For persistent AF, defined as continuous AF that sustains longer than 7 days, the success rate is even lower. The low success rate of AF ablation reflects the fact that there is no effective target identified to modify the underlying substrate beyond PVI. Recently, investigators have made an exciting discovery that higher mean CT attenuation values of peri-atrial fat tissue, correlated with inflammatory fat, are associated with higher incidence of recurrence after AF ablation (Ciuffo at el., Circ Cardiovasc Imaging 2019;12:e008764). In this protocol, investigators will investigate the clinical significance of peri-atrial inflammatory fat tissue in AF using ultra-high resolution CT.
This protocol entails preliminary studies to demonstrate feasibility and inform effect size, sample size and power estimates for future studies designed to test the efficacy of inflammatory fat-targeted ablation in a larger prospective randomized study.
Investigators will prospectively enroll 300 patients referred to the Johns Hopkins Hospital for catheter ablation of AF, consisting of patients with paroxysmal AF (n=100), persistent AF (n=100) and recurrent AF/AFL post-AF ablation (n=100) (Figure 3). All the patients will undergo pre-procedural CT using the ultra-high resolution CT scanner. If the ultra-high resolution CT is not available on the day of the CT scan, the patient may instead undergo pre-procedural CT using a standard CT scanner. The CT protocol will be the standard prospectively-gated CT scan to minimize radiation exposure to the patient. No functional information is needed. Compared with the standard CT scanner, the ultra-high resolution CT is expected to provide finer details of inflammatory fat structure and distribution over the per-atrium.
The patients with paroxysmal AF will receive the standard of care, which is PVI, and the clinical outcome will be followed up to 12 months post-procedure. For the patients with persistent AF and recurrent AF/ Atrial Flutter (AFL), there is no standard of care as to how to perform ablation beyond repeating PVI. In an attempt to reduce the likelihood of recurrence, most electrophysiologists combine PVI with additional empiric ablation strategies to modify the underlying arrhythmic substrate, such as linear lesions (e.g. roof lines, mitral isthmus lines), focal ablation to eliminate complex fractionated atrial electrograms (CFAE) and rotating drivers. Nevertheless, prospective randomized studies demonstrate that these empiric ablation strategies do not improve clinical outcomes compared with PVI alone. In this protocol, the patients with persistent AF and recurrent AF/AFL will be randomly split into two groups: 1) PVI group, and 2) PVI + fat ablation group, where additional ablation is performed to target the inflammatory fat tissue. The clinical outcome will be followed up to 12 months post-procedure.
In all the patients, two sets of blood specimens (total <20 mL) will be collected at the time of the procedure: one set is from the peripheral venous blood, and the other from the coronary sinus blood. Those samples will be sent to quantify the fat and inflammatory biomarkers (e.g. adipokines, cytokines, high-sensitivity troponin T [hsTnT]) to evaluate the local and systemic effect of inflammation.
Not yet recruiting
Johns Hopkins University
Published on BioPortfolio: 2019-12-10T01:20:59-0500
The study will assess the atrial fibrillation burden recorded By implantable loop recorder at 12 and 24 months compared to baseline. The patients with clinical indication fo catheter ablat...
There is a need to compare the efficacy of PVI versus PVI plus catheter ablation, which includes ablation of complex fractionated atrial electrograms (CFAE) and linear lesions in the same ...
Atrial fibrillation (AF) and atrial tachycardia (AT), including type I atrial flutter, are frequently observed in patients with pulmonary hypertension (PH). Catheter ablation of AF / AT ha...
Prospective randomized observational trial comparing the efficacy of circumferential pulmonary vein ostia ablation using surgical versus catheter techniques in the treatment of paroxysmal ...
Patents with atrial fibrillation can be treated with the purpose of curing the arrhythmia.This may be achieved by catheter ablation and Maze surgery where the latter includes open heart su...
Patients with atrial fibrillation (AF) often undergo repeat catheter ablation for recurrence of tachyarrhythmia. If the pulmonary veins were isolated in prior procedure, the operator should focus on s...
Few studies evaluated the impact of catheter ablation (CA) on atrial tachyarrhythmia (ATA) burden in paroxysmal atrial fibrillation (AF).
Left atrial low voltage areas (LVA) are associated with increased recurrence rates of atrial fibrillation (AF) after catheter ablation and can be a potential ablation target during the procedure. Ther...
The impact of intra-atrial conduction delay on the recurrence of atrial tachyarrhythmia after radio frequency catheter ablation (RFCA) has not been fully elucidated.
Catheter ablation for atrial fibrillation (CAF) improves symptoms, but whether CAF improves outcome is less clear. The purpose of this study was to investigate whether CAF is associated with improved ...
Rapid, irregular atrial contractions caused by a block of electrical impulse conduction in the right atrium and a reentrant wave front traveling up the inter-atrial septum and down the right atrial free wall or vice versa. Unlike ATRIAL FIBRILLATION which is caused by abnormal impulse generation, typical atrial flutter is caused by abnormal impulse conduction. As in atrial fibrillation, patients with atrial flutter cannot effectively pump blood into the lower chambers of the heart (HEART VENTRICLES).
Long-term changes in the electrophysiological parameters and/or anatomical structures of the HEART ATRIA that result from prolonged changes in atrial rate, often associated with ATRIAL FIBRILLATION or long periods of intense EXERCISE.
A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666)
The pressure within the CARDIAC ATRIUM. It can be measured directly by using a pressure catheter (see HEART CATHETERIZATION). It can be also estimated using various imaging techniques or other pressure readings such as PULMONARY CAPILLARY WEDGE PRESSURE (an estimate of left atrial pressure) and CENTRAL VENOUS PRESSURE (an estimate of right atrial pressure).
Removal of tissue with electrical current delivered via electrodes positioned at the distal end of a catheter. Energy sources are commonly direct current (DC-shock) or alternating current at radiofrequencies (usually 750 kHz). The technique is used most often to ablate the AV junction and/or accessory pathways in order to interrupt AV conduction and produce AV block in the treatment of various tachyarrhythmias.
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza, Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...